Resmed (RMD) announced it has received U.S. Food and Drug Administration, FDA, clearance for Personalized Therapy Comfort Settings, PTCS, to be marketed as Smart Comfort. Smart Comfort is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings to help people with obstructive sleep apnea, OSA, start and stay on CPAP therapy. Smart Comfort will launch in early 2026 in a limited U.S. beta version for new users of myAir, Resmed’s consumer sleep companion app, paired with a Resmed AirSense 11 device. It will be followed by a broader U.S. rollout to new myAir users later in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Resmed’s Strategic Positioning and Market Valuation Suggest 19% Upside Despite Future CMS Challenges
- ResMed removed from APAC Conviction List at Goldman Sachs
- ResMed Streamlines Governance at Annual Meeting
- ResMed price target lowered to $300 from $320 at Baird
- ResMed Inc. Reports Strong Q1 Earnings Amid Growth Challenges